READ THIS – If You Missed Out On The AI Boom

Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”

Click on Adam's shiny forehead for more details.

Ronald Rittenmeyer Biography and Net Worth

Director of IQVIA

Ronald A. Rittenmeyer has served as a director of IQVIA since October 2016. Prior to this, Mr. Rittenmeyer served as a Director of IMS Health from April 2010 to October 2016. He served as Chairman, President and CEO of Expert Global Solutions, Inc. from 2008 to June 2014. Prior to that, Mr. Rittenmeyer served as Chairman, CEO and President of Electronic Data Systems Corporation from 2005 until 2008.He served as Chief Operating Officer of Electronic Data Systems Corporation from October 2005 until September 2007 (including service as Co-Chief Operating Officer until May 2006) and as Executive Vice President, Global Service Delivery from July 2005 until December 2006. Mr. Rittenmeyer also serves on the boards of directors of American International Group, Inc. and Tenet Health Care Corporation. He previously served as a director of EDS and RH Donnelley (presently Dex One Corporation). Mr. Rittenmeyer has a bachelor of arts degree in Commerce and Economics from Wilkes University, and his MBA from Rockhurst University. Mr. Rittenmeyer chairs the Leadership Development and Compensation Committee and serves as a member of the Audit Committee.

What is Ronald A. Rittenmeyer's net worth?: The estimated net worth of Ronald A. Rittenmeyer is at least $223.27 million as of December 10th, 2020. Mr. Rittenmeyer owns 958,494 shares of IQVIA stock worth more than $223,271,592 as of May 1st. This net worth evaluation does not reflect any other investments that Mr. Rittenmeyer may own. Learn More about Ronald A. Rittenmeyer's net worth.
How do I contact Ronald A. Rittenmeyer?: The corporate mailing address for Mr. Rittenmeyer and other IQVIA executives is 4820 EMPEROR BOULEVARD, DURHAM NC, 27703. IQVIA can also be reached via phone at (919) 998-2000 and via email at [email protected]. Learn More on Ronald A. Rittenmeyer's contact information.
Has Ronald A. Rittenmeyer been buying or selling shares of IQVIA?: Ronald A. Rittenmeyer has not been actively trading shares of IQVIA during the past quarter. Most recently, Ronald A. Rittenmeyer sold 9,590 shares of the business's stock in a transaction on Tuesday, November 24th. The shares were sold at an average price of $172.96, for a transaction totalling $1,658,686.40. Following the completion of the sale, the director now directly owns 11,894 shares of the company's stock, valued at $2,057,186.24. Learn More on Ronald A. Rittenmeyer's trading history.
Who are IQVIA's active insiders?: IQVIA's insider roster includes Ari Bousbib (Insider), Ronald Bruehlman (Insider), John Connaughton (Director), John Danhakl (Director), Kevin Knightly (Insider), Michael McDonnell (CFO), Ronald Rittenmeyer (Director), and Eric Sherbet (Insider). Learn More on IQVIA's active insiders.
Are insiders buying or selling shares of IQVIA?: In the last year, insiders at the medical research company sold shares 7 times. They sold a total of 87,540 shares worth more than $20,013,870.89. The most recent insider tranaction occured on March, 1st when insider Ari Bousbib sold 31,678 shares worth more than $7,936,289.34. Insiders at IQVIA own 1.6% of the company. Learn More about insider trades at IQVIA.
Information on this page was last updated on 3/1/2024.

Ronald A. Rittenmeyer Insider Trading History at IQVIA

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/24/2020	Sell	9,590	$172.96	$1,658,686.40	11,894
2/5/2019	Sell	3,840	$130.00	$499,200.00
7/26/2018	Sell	7,680	$122.41	$940,108.80

Ronald A. Rittenmeyer Buying and Selling Activity at IQVIA

IQVIA Company Overview

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.

Today's Range

Now: $232.94

$229.58

$237.56

50 Day Range

MA: $245.15

$227.17

$259.15

2 Week Range

Now: $232.94

$167.42

$261.73

Volume

1,025,515 shs

Average Volume

964,444 shs

Market Capitalization

$42.28 billion

P/E Ratio

31.95

Dividend Yield

N/A

Beta

1.5